Literature DB >> 2955795

Immune pathogenesis of AIDS and related syndromes.

J L Fahey, J Giorgi, O Martínez-Maza, R Detels, R Mitsuyasu, J Taylor.   

Abstract

HIV infection induces both immune deficiency and immune stimulation. Central to the pathology of HIV infection is reduction in the numbers and function of CD4 T cells. Impaired functions include decreased proliferation, IL-2 receptor expression and production of lymphokines (IL-2 and gamma interferon (IFN]. HIV infection stimulates B cells and CD8 T cells. This is seen relatively soon after HIV infection. Increased activation and immaturity are seen in both these cell groups. In vitro studies confirm HIV stimulation of these cells. Studies have been conducted on patients with AIDS and opportunistic infection (OI) or Kaposi's sarcoma (KS), with AIDS-related complex (ARC) or with persistent generalized lymphadenopathy (PGL), as well as on asymptomatic HIV-seropositive and -seronegative homosexually active men. The latter group has been followed at 6-month intervals for the past 2-3 years. Those who seroconverted (became HIV-infected) were studied to investigate early changes following HIV infection. To delineate the immunopathology of infection with HIV, serial testing of seropositive individuals was carried out to determine the rate of CD4-T-cell reduction. Lowered CD4-T-cell number and percentage and CD4/CD8 ratio correlate with the occurrence of AIDS and with survival after AIDS-KS diagnosis. Seropositive individuals, however, differed markedly in the rate of CD4-T-cell reduction; in some, no reduction in CD4 cells occurred over a two-year period of observation. We propose that, in individuals in which CD4 levels have reached a plateau, effective host resistance to further CD4 cytoreduction has occurred.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955795     DOI: 10.1016/s0769-2625(87)80075-2

Source DB:  PubMed          Journal:  Ann Inst Pasteur Immunol        ISSN: 0769-2625


  8 in total

Review 1.  Lymphocyte subsets as surrogate markers in antiretroviral therapy.

Authors:  J R Bogner; F D Goebel
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice.

Authors:  Kaori Sango; Aviva Joseph; Mahesh Patel; Kristin Osiecki; Monica Dutta; Harris Goldstein
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

3.  Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Authors:  E Ojo-Amaize; P G Nishanian; D F Heitjan; A Rezai; I Esmail; E Korns; R Detels; J Fahey; J V Giorgi
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

Review 4.  Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 5.  Standardizing immunophenotyping for the Human Immunology Project.

Authors:  Holden T Maecker; J Philip McCoy; Robert Nussenblatt
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 6.  Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?

Authors:  Guido Vanham; Ellen Van Gulck
Journal:  Retrovirology       Date:  2012-09-07       Impact factor: 4.602

Review 7.  Eradication of HIV and Cure of AIDS, Now and How?

Authors:  Jielin Zhang; Clyde Crumpacker
Journal:  Front Immunol       Date:  2013-10-18       Impact factor: 7.561

8.  Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Authors:  Victor Leung; Jennifer Gillis; Janet Raboud; Curtis Cooper; Robert S Hogg; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Sean B Rourke; Chris Tsoukas; Marina B Klein
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.